Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,042 shares of the biopharmaceutical company's stock after buying an additional 4,976 shares during the quarter. Janney Montgomery Scott LLC's holdings in Regeneron Pharmaceuticals were worth $17,785,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in REGN. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 15 shares during the last quarter. Adirondack Trust Co. grew its stake in shares of Regeneron Pharmaceuticals by 4.2% during the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 18 shares in the last quarter. Financial Perspectives Inc grew its stake in shares of Regeneron Pharmaceuticals by 10.9% during the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock worth $137,000 after purchasing an additional 19 shares in the last quarter. Finally, Prestige Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals by 23.2% in the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after buying an additional 19 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $4.72 during mid-day trading on Thursday, hitting $513.58. The stock had a trading volume of 841,026 shares, compared to its average volume of 884,759. The company has a 50 day simple moving average of $559.88 and a 200 day simple moving average of $645.05. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The company has a market cap of $55.45 billion, a price-to-earnings ratio of 13.07, a P/E/G ratio of 1.86 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $9.55 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.69%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on REGN. UBS Group decreased their price target on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating for the company in a report on Thursday, June 5th. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Bank of America cut their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Finally, Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.